Prescription Drug Affordability Board Reports

State-focused monthly reports providing you with the latest developments in PDAB activities.

Prescription Drug Affordability Boards (PDABs) are rapidly gaining momentum to address prescription drug costs. With six states already having established PDABs, and others in the process of establishing their own, closely monitoring and evaluating their advancements has become imperative for businesses.

The specific duties of PDABs and similar groups may vary from state to state; however, most possess the authority to review the cost of prescription drugs, assess their affordability, set upper payment limits (UPLs), engage with drug manufacturers, and advocate for transparency in prescription drug pricing.

At Stateside, we are tracking the progress of PDAB activities and have curated monthly reports containing state-specific information that will keep you well-informed on the latest developments and important updates. 

Our reports include:

  • Meeting summaries that include board recommendations and proposed rules so you can stay ahead of the curve and identify potential impacts on your business. 
  • Upcoming meeting dates and agendas so you can plan and provide input to the board.
  • Information on Board Members and other Councils that may assist in building relationships with stakeholders.

For questions or to request a sample report, please contact:

Zach Cook_Stateside Associates

Zachary Cook
Senior Director & Counsel, Health Care Policy

phone: (703) 525-7466 ext. 247

Current Updates with Prescription Drug Affordability Boards (PDABs)
States with an Established PDAB States with Active Legislation to Create PDABs States Discussing PDABs
Colorado Arizona
Maine Connecticut
Maryland Illinois
Minnesota Iowa
New Hampshire Michigan
New Jersey* Nebraska
Oregon New Jersey**
Washington New York
South Carolina

Data as of February 28, 2024

*New Jersey has created a Drug Affordability Council, which has the authority to recommend affordability strategies.

**New Jersey has proposed the creation of the Prescription Drug and Biological Product Review Commission, which would have the authority to set upper payment limits


Request a Sample Report Below